AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 AUG 6 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A novel adenovirus-based vaccine against the simian version of HIV (SIV) has delivered promising results in a macaque model of infection, researchers in the United States report.
Jun Zhao and colleagues at the National Cancer Center in Bethesda, Maryland, the Duke University Medical Center in Durham, North Carolina, and Advanced BioScience Laboratories, Inc., in Kensington, Maryland "investigated the ability of a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen to induce protective immunity in rhesus macaques against pathogenic simian immunodeficiency virus[subscript]mac251."
Although it did not completely protect against infection, this regimen produced robust cellular and humoral anti-SIV immune activity, Zhao and coauthors found.
All of the immunized animals developed SIV-neutralizing serum antibodies, with immunoglobulin G (IgG) and IgA antibodies targeting the SIV coat protein gp120 seen in secretory fluids, the researchers said. Vaccinated animals also showed anti-SIV T-cell activity for more than 10 months after treatment.
While all of the immunized macaques became infected with SIV after challenge, 8 of 12 animals had significantly reduced viremia compared to controls, study data indicated. None of these eight macaques carried Mamu-A*01, a major histocompatibility complex (MHC) ...